Influence of hepatic impairment on the pharmacokineticsand pharmacodynamics of the P2Y12 receptor antagonist selatogrel

First published in Clinical and Translational Science on 2022 Aug.
Clin Transl Sci. 2022 Aug;15(8):1906-1915. doi: 10.1111/cts.13298. Epub 2022 May 18

Authors: Schilling U, Hsin CH, Delahaye S, Krause A, Wuelfrath H, Halabi A, Dingemanse J.

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE

+49 621 150 45 – 0

Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

+49 621 150 45 – 0

Influence of hepatic impairment on the pharmacokineticsand pharmacodynamics of the P2Y12 receptor antagonist selatogrel

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.

(Bersacapavir) In Participants With Moderate Hepatic Impairment.